Results 61 to 70 of about 618,549 (318)
REPORT OF THE BLADDER TUMOR STUDY GROUP IN OSAKA (1) REGIONAL DISTRIBUTION OF PATIENTS WITH BLADDER TUMOR IN OSAKA PREFECTURE [PDF]
This is a statistical study of age and sex, chief complaints and regional distribution of 850 patients with bladder tumors who consulted the urological clinics belonging to the Bladder Tumor Study Group in Osaka during the one and a half years from ...
大阪膀胱腫瘍研究会
core
Background and aims Several non-invasive tests for detecting bladder cancer (BC) are commercially available and are based on detecting small panels of BC-associated mutations and/or methylation changes in urine DNA. However, it is not clear which type of
Naheema S. Gordon +14 more
doaj +1 more source
ABSTRACT Objective To delineate specific in vivo white matter pathology in neuronal intranuclear inclusion disease (NIID) using diffusion spectrum imaging (DSI) and define its clinical relevance. Methods DSI was performed on 42 NIID patients and 38 matched controls.
Kaiyan Jiang +10 more
wiley +1 more source
Botulinum toxin-A for the treatment of overactive bladder: UK contributions
Background: Botulinum toxin-A (BoNT/A) is now established second-line management for refractory overactivebladder (OAB) and recognised in many incontinence guidelines and pathways.
Fowler, CJ +13 more
core +1 more source
Background The latest bladder cancer (BC) urine tests based on multiple genomic and/or epigenomic markers detect BC with high sensitivity and specificity.
Jessica L Neil +13 more
doaj +1 more source
Intrinsic subtypes and bladder cancer metastasis
Recent studies demonstrated that bladder cancers can be grouped into basal and luminal molecular subtypes that possess distinct biological and clinical characteristics.
David J. McConkey +3 more
doaj +1 more source
ABSTRACT Objective To (1) validate GAD65‐ELISA detection and quantification for type 1 diabetes mellitus and autoimmune neurological diagnoses, (2) correlate ELISA results (reference range < 5 IU/mL) with established radioimmunoprecipitation assay (RIA; ≤ 0.02 nmol/L), and (3) define ELISA clinical utility and pitfalls.
Andrew McKeon +11 more
wiley +1 more source
The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression [PDF]
Background: New methods for identifying bladder cancer (BCa) progression are required. Gene expression microarrays can reveal insights into disease biology and identify novel biomarkers.
Wild, P J +50 more
core +1 more source
Added Prognostic Value of EEG Reactivity in Comatose Patients Following Cardiac Arrest
ABSTRACT Objectives To evaluate the added prognostic value of EEG reactivity for favorable outcome compared with background analysis during and after targeted temperature management (TTM). Methods Prospective observational cohort study of comatose post–cardiac arrest patients admitted to a single academic center between 2017 and 2022, all undergoing ...
Sarah Caroyer +11 more
wiley +1 more source
Measurements of complement factor H-related protein (BTA-TRAK (TM) assay) and nuclear matrix protein (NMP22 assay) - Useful diagnostic tools in the diagnosis of urinary bladder cancer? [PDF]
Between 1997 and 2000 we investigated in a prospective study the voided urine samples of all consecutive patients undergoing cystoscopy independent from their clinical background (n=705) with the BTA-TRAK(TM) assay (Bard Diagnostics, Redmont, USA ...
Holdenrieder, Stefan +17 more
core +1 more source

